Priti Hegde

Summary

Affiliation: Genentech Inc
Country: USA

Publications

  1. doi request reprint Predictive impact of circulating vascular endothelial growth factor in four phase III trials evaluating bevacizumab
    Priti S Hegde
    Department of Oncology Biomarkers, Genentech, Inc, South San Francisco, CA 94080, USA
    Clin Cancer Res 19:929-37. 2013
  2. pmc Development of a robust flow cytometry-based pharmacodynamic assay to detect phospho-protein signals for phosphatidylinositol 3-kinase inhibitors in multiple myeloma
    Congfen Li
    Genentech Inc, South San Francisco, CA 94080, USA
    J Transl Med 11:76. 2013

Collaborators

  • Congfen Li
  • Joanna Lee
  • Basha Stankovich
  • Mark R Lackner
  • Liangxuan Zhang
  • Jeff Eastham Anderson
  • Marcin Kowanetz
  • Kathy Howell
  • Matthew J Brauer
  • Shidong Jia
  • Yibing Yan
  • Dorothy French
  • Eric Humke
  • Mahrukh Huseni
  • Chikara Takahashi
  • Haider Mashhedi
  • Allen Ebens
  • Garret Hampton
  • Doris Kim

Detail Information

Publications2

  1. doi request reprint Predictive impact of circulating vascular endothelial growth factor in four phase III trials evaluating bevacizumab
    Priti S Hegde
    Department of Oncology Biomarkers, Genentech, Inc, South San Francisco, CA 94080, USA
    Clin Cancer Res 19:929-37. 2013
    ..We evaluated the prognostic and predictive use of circulating VEGF-A levels in phase III trials of bevacizumab in colorectal cancer, lung cancer, and renal cell carcinoma...
  2. pmc Development of a robust flow cytometry-based pharmacodynamic assay to detect phospho-protein signals for phosphatidylinositol 3-kinase inhibitors in multiple myeloma
    Congfen Li
    Genentech Inc, South San Francisco, CA 94080, USA
    J Transl Med 11:76. 2013
    ..This study aimed to develop a robust clinical pharmacodynamic (PD) assay to measure the on-target PD effects of the selective PI3K inhibitor GDC-0941 in MM patients...